Clinical-stage biotechnology firm Atreca has signed a licensing agreement with the Bill & Melinda Gates Medical Research Institute (Gates MRI) for the development of a monoclonal antibody to prevent malaria.
Amgen has completed its previously announced acquisition of a clinical-stage biotechnology firm, Teneobio in a deal worth up to $2.5bn.
Silence Therapeutics has announced collaboration with Hansoh Pharmaceutical to develop new therapeutics using Silence’s mRNAi GOLD platform.
Exelixis has signed an exclusive collaboration and license agreement with STORM Therapeutics to discover and develop inhibitors of novel RNA modifying enzymes.
Intellia Therapeutics, and SparingVision have entered into a strategic collaboration to develop new genomic medicines making use of CRISPR/Cas9 technology to treat ocular diseases.
The US Food and Drug Administration (FDA) has approved biologics license application (sBLA) and the European Medicines Agency (EMA) has validated the type-II variation application for Novartis’ Beovu (brolucizumab) to treat patients with diabetic macular edema (DME).
Poseida Therapeutics has signed a research collaboration and license agreement with Takeda Pharmaceutical Company to develop up to eight in vivo gene therapy programmes.
Pacira BioSciences has signed a definitive agreement to acquire biopharmaceutical firm Flexion Therapeutics to strengthen its position in non-opioid pain management.
The US Food and Drug Administration (FDA) has accepted the filing of a new drug application (NDA) for Acer Therapeutics and Relief Therapeutics’ ACER-001 (sodium phenylbutyrate) to treat people with urea cycle disorders (UCDs).
AstraZeneca’s subsidiary Alexion has announced plans to acquire all the remaining equity stake in Caelum Biosciences for up to $500m.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.